Dr. Mato on what really happens when we must s... - CLL Support

CLL Support

22,369 members38,477 posts

Dr. Mato on what really happens when we must stop our ibrutinib or idelalisib

bkoffman profile image
bkoffmanCLL CURE Hero
7 Replies

Friends,

I hope my US-based readers had a happy healthy holiday weekend. This past weekend, in addition to recovering from my Paris jetlag, I have been reading abstracts in preparation to travel to the European Hematology Association meeting next Monday in Copenhagen. The meeting doesn’t start until Thursday, but I’ll be presenting some preliminary data from our Reader Poll at a symposium on Wednesday. Thanks again to those participants for taking the time to participate.

This week in the Conference Coverage section of the CLL Society website, we’ve posted an interview from ASH 2015 with Dr. Anthony Mato out of the University of Pennsylvania. He, along with 9 other institutions gathered data about their patients who discontinued either ibrutinib or idelalisib. You can read about the study and watch my interview with Dr. Mato here. [ cllsociety.org/2016/05/ash-... ]

I also wrote a brief blog post bkoffman.blogspot.com on what stops us from getting our best personalized care and how our little nonprofit is trying to help.

From time to time, we will make you aware of in-person meetings coming up for those of us affected by CLL. In June, they include:

June 16th at 6 PM in Salt Lake City, UT: The Lymphoma Research Foundation will be hosting Updates on Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma as part of their Ask the Doctor series. You can find out more information and register here. There is no charge to attend. [ lymphoma.org/site/pp.asp?c=... ]

I off to EHA in Copenhagen next week- meeting with fellow advocates from Europe and trying to represent the patients' perspective with your help on the surveys.

In the meantime….

Stay strong.

We are all in this together.

Brian Koffman, MD

Volunteer Medical Director of the CLL Society

5/31/16

Written by
bkoffman profile image
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Read more about...
7 Replies
LynnB1947 profile image
LynnB1947

Thanks for sharing Dr. Koffman. As I have been on ibrutinib now for 25 months, I am very interested in following future options. Side-effects on ibrutinib for me have been the usual annoyances & nothing major. Your posts have great interest to the CLL/SLL community because as you say, "we're all in this together."

Lynn

bkoffman profile image
bkoffmanCLL CURE Hero in reply to LynnB1947

Thanks. New therapies are coming, but they are not perfect.

Justasheet1 profile image
Justasheet1 in reply to bkoffman

Doc,

What is perfect. Are you optimistic or is this an off year?

Jeff

bkoffman profile image
bkoffmanCLL CURE Hero

Nothing perfect coming, but therapies keep getting better.

Justasheet1 profile image
Justasheet1 in reply to bkoffman

Doc,

As you say,"stuck on third base".

Jeff

bkoffman profile image
bkoffmanCLL CURE Hero

And sometime the next 3 batters at the plate strike out.

Justasheet1 profile image
Justasheet1

Doc,

Let's hope it's early enough in the season. You never know when that hitting streak will begin.

Jeff

You may also like...

Dr. Mato on Sequencing and what is CLLAN

working in this interview from ASH 2019...

ASH 2016: Dr. Mato on real world data on ibrutinib

I'm posting an interview that I had with Dr. Anthony Mato from U Penn when we talked at ASH 2016...

Dr Sharman's thoughts on the race for FDA Approval for Obinituzumab, Ibrutinib and Idelalisib

Obinituzumab, Ibrutinib and Idelalisib and has written at length about the likely approval process...

Zanubrutinib vs. Ibrutinib Patient Power Video by Dr. Jennifer Brown MD PHD

updates our chronic lymphocytic leukemia (CLL) patients on the latest from the 2022 American...

Top 10 list of what we need to know about lymphoma

of what we need to know about lymphoma on our nonprofit's website: http://cllsociety.org. Remember...